-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $157

Benzinga·12/12/2025 17:56:29
语音播报
Goldman Sachs analyst Corinne Jenkins maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $141 to $157.